For molecular mechanisms, this finding revealed that silencing RIG-I inactivated NF-κB. Furthermore, PDTC, a NF-κB inhibitor, could eliminate RIG-I effects on CRC tumor growth and glucose metabolism. The gene discussed is NFKB1; the disease is colorectal carcinoma.